Recombinant Human MDR1 Protein，His

MDR1, or Multidrug Resistance Protein 1, is a crucial member of the ATP-binding cassette (ABC) transporter family, primarily responsible for the efflux of various substrates, including drugs, from cells. Its overexpression is commonly associated with multidrug resistance (MDR) in cancer cells, where it diminishes the efficacy of chemotherapeutic agents by pumping them out of the cells before they can exert their therapeutic effects. This phenomenon presents a significant challenge in cancer treatment, leading to treatment failures and poor patient outcomes. Research on MDR1 recombinant protein has gained momentum in recent years, aiming to elucidate its structural and functional characteristics, as well as its role in drug transport mechanisms. Investigators are focusing on the production of recombinant MDR1 proteins to study their interactions with substrates and inhibitors, which can help in designing effective strategies to overcome drug resistance. Furthermore, the study of MDR1 is critical for improving drug formulation and delivery systems, thereby enhancing the therapeutic index of various anticancer drugs. Understanding the molecular basis behind MDR1-mediated drug resistance may also pave the way for novel therapeutic interventions, including the development of MDR1 inhibitors or the use of nanocarriers that bypass the efflux mechanisms. Overall, MADR1 recombinant protein research is vital for advancing our knowledge of multidrug resistance and improving outcomes in cancer therapy.